摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

CBCV | 57130-04-8

中文名称
——
中文别名
——
英文名称
CBCV
英文别名
cannabichromevarin;cannabichromenevarin;2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol
CBCV化学式
CAS
57130-04-8
化学式
C19H26O2
mdl
——
分子量
286.414
InChiKey
AAXZFUQLLRMVOG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    401.4±45.0 °C(Predicted)
  • 密度:
    1.009±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    CBCV 在 iron(III) chloride 作用下, 以 氟苯 为溶剂, 反应 12.0h, 以75%的产率得到cannabicyclovarin
    参考文献:
    名称:
    Efficient and novel one-pot synthesis of polycycles bearing cyclols by FeCl3-promoted [2 + 2] cycloaddition: application to cannabicyclol, cannabicyclovarin, and ranhuadujuanine A
    摘要:
    利用 FeCl3 促进的 [2 + 2] 环加成反应,从容易获得的具有多种取代基的苯并吡喃中开发出简单易行的合成路线,用于制备具有生物学意义的环醇多环。作为该方法的例子,大麻二环醇、大麻二环素和ranhuadujuanine A 的一步合成以良好的产率完成。
    DOI:
    10.1039/c3ob42110d
  • 作为产物:
    描述:
    1,3-dimethoxy-5-(prop-1-en-1-yl)benzene 在 palladium 10% on activated carbon 、 氢气三溴化硼ethylenediamine Tetraacetic Acid 作用下, 以 甲醇二氯甲烷甲苯 为溶剂, 反应 18.0h, 生成 CBCV
    参考文献:
    名称:
    次要大麻素作为皮肤炎症抑制剂:化学合成和生物学评价
    摘要:
    尽管治疗性植物的使用已有数千年的历史,但对大麻多样化生物医学潜力的有意开发直到最近才引起人们的关注。生物活性研究主要集中在大麻二酚(CBD)和四氢大麻酚(THC)上,有关更广泛的大麻组“次要植物大麻素”的信息有限。在此背景下,我们的研究目标是合成含有 3 或 4 个碳原子侧链的次要大麻素,重点是大麻醇 (CBG) 和大麻色烯 (CBC) 类似物。利用已知的创新策略,我们合成了 11 种 C3 和 C4 类似物,其中 5 种是皮肤炎症抑制剂,其中 CBG-C4 酯衍生物成为最有效的化合物。
    DOI:
    10.1021/acs.jnatprod.4c00212
点击查看最新优质反应信息

文献信息

  • [EN] SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP<br/>[FR] SYNTHÈSE DE PHYTOCANNABINOÏDES COMPRENANT UNE ÉTAPE DE DÉCARBOXYLATION
    申请人:UNIV SYDNEY
    公开号:WO2019033168A1
    公开(公告)日:2019-02-21
    method for decarboxylating a carboxylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C1-C5 alkyl; R2 is selected from the group consisting of: OH or O, and R3 is selected from the group consisting of: a substituted or unsubstituted cyclohexene, a substituted or unsubstituted C2-C8 alkene, or a substituted or unsubstituted C2-C8 dialkene; or R2 is O, and R2 and R3 together form a ring structure in which R2 is an internal ring atom; wherein the method includes heating a reaction mixture comprising the carboxylated phytocannabinoid compound and a polar aprotic solvent in the presence of a LiCl for a time sufficient to decarboxylate at least a portion of the carboxylated phytocannabinoid compounds and form the phytocannabinoid compound.
    化学方程式中的羧基化植物大麻化合物(Formula I)脱羧成形成另一种植物大麻化合物(Formula II)的方法:Formula I Formula II 其中:R1选自以下组合:取代或未取代的C1-C5烷基;R2选自以下组合:OH或O;R3选自以下组合:取代或未取代的环己烯,取代或未取代的C2-C8烯烃,或取代或未取代的C2-C8二烯烃;或者R2为O,且R2和R3共同形成一个环结构,其中R2是内环原子;该方法包括在存在LiCl的情况下,加热含有羧基化植物大麻化合物和极性非质子溶剂的反应混合物,以足够时间脱羧至少部分羧化植物大麻化合物并形成植物大麻化合物。
  • One-Pot Total Synthesis of Cannabinol via Iodine-Mediated Deconstructive Annulation
    作者:Diego Caprioglio、Daiana Mattoteia、Alberto Minassi、Federica Pollastro、Annalisa Lopatriello、Eduardo Muňoz、Orazio Taglialatela-Scafati、Giovanni Appendino
    DOI:10.1021/acs.orglett.9b02258
    日期:2019.8.2
    coupled, in an aromatization-driven single operational step, the condensation of citral and alkylresorciniols to homoprenylchromenes and their in situ deconstructive annulation to benzo[c]chromenes. This process was applied to a total synthesis of cannabinol (CBN, 5) and to its molecular editing.
    大麻素(CBC,3)的热降解主要受阳离子反应的影响,而不是模型化合物中观察到的周环重排。这些差异的合理化激发了工艺的发展,该工艺在芳构化驱动的单个操作步骤中将柠檬醛和烷基间苯二酚缩合为高异戊二烯基色烯,并将它们原位解构性环化为苯并[ c ]色烯。此过程应用于大麻酚(CBN,5)的全合成及其分子编辑。
  • CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE
    申请人:Emerald Health Biotechnology España,S.L.U.
    公开号:EP3666765A1
    公开(公告)日:2020-06-17
    The present invention relates to a compound of the formula (I) or a solvate or co-crystal thereof wherein: - R is selected from the group consisting of: a C1-C6 alkyl, a C2-C8 alkenyl moiety, a C4-C12 dienyl or a C6-C18 trienyl moiety; - R1 is a C1-C6 alkyl moiety; - R2 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R3 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R4 is selected from the group consisting of: H, a C1-C6 alkyl moiety and a benzyl moiety. The present invention also relates to a process for producing said compound of the formula (I), or a solvate or co-crystal thereof, as well as a pharmaceutical composition comprising said compound of the formula (I), or a solvate or co-crystal thereof and at least one excipient. The present invention also relates to a compound of the formula (I), or a solvate or co-crystal thereof, for use in the treatment or prevention of a disease or condition.
    本发明涉及以下公式(I)的化合物或其溶剂或共晶体,其中:- R选自以下组:C1-C6烷基,C2-C8烯基基团,C4-C12二烯基或C6-C18三烯基;- R1是C1-C6烷基基团;- R2选自以下组:H和C1-C6烷基基团;- R3选自以下组:H和C1-C6烷基基团;- R4选自以下组:H,C1-C6烷基基团和苄基。本发明还涉及制备所述公式(I)的化合物或其溶剂或共晶体的方法,以及包括所述公式(I)的化合物或其溶剂或共晶体和至少一种赋形剂的药物组合物。本发明还涉及用于治疗或预防疾病或状况的公式(I)的化合物或其溶剂或共晶体。
  • Cannabinoid composition and products including α-tocopherol
    申请人:Constance Therapeutics, Inc.
    公开号:US10238745B2
    公开(公告)日:2019-03-26
    A cannabinoid composition having an excipient including α-tocopherol and at least one isolated cannabinoid having a purity of greater than 80%. The α-tocopherol inhibits oxidation, regulates viscosity of the composition, and improves bioavailability of the cannabinoid. The composition includes a carrier oil mixed with the excipient and cannabinoid. In one embodiment, the at least one cannabinoid is an isolated cannabinoid having a greater than 80% purity, and preferably greater than 90% purity. The at least one cannabinoid is selected from the group consisting of phytocannabinoids, endocannabinoids, synthetic cannabinoids, and combinations thereof. The cannabinoid may be derived from plants other than cannabis sativa, or synthesized from fungi, bacteria, yeast or other synthetic method. Preferably the α-tocopherol comprises at least 10% w/w of the composition.
    一种大麻素组合物,其赋形剂包括α-生育酚和至少一种纯度大于 80% 的分离大麻素。α-生育酚可抑制氧化,调节组合物的粘度,提高大麻素生物利用度。组合物包括与赋形剂和大麻素混合的载体油。在一个实施方案中,至少一种大麻素是分离出来的大麻素,纯度大于 80%,最好大于 90%。至少一种大麻素选自植物大麻素、内源性大麻素、合成大麻素及其组合组成的组。大麻素可以从大麻以外的植物中提取,也可以从真菌、细菌、酵母或其他合成方法中合成。α-生育酚最好至少占组合物重量的 10%。
  • Apparatus, methods and composition for synthesis of cannabinoid compounds
    申请人:TEEWINOT TECHNOLOGIES LIMITED
    公开号:US10336978B2
    公开(公告)日:2019-07-02
    The disclosure provides systems and methods for producing a cannabinoid product, which comprises contacting a cannabinoid precursor in a first phase with a cannabinoid synthase in a second phase, wherein the first phase and the second phase are substantially immiscible or immiscible. The disclosure also provides a composition comprising the cannabinoid precursor in a first phase and a cannabinoid synthase in a second phase, wherein the first phase and the second phase are substantially immiscible or immiscible.
    本公开提供了生产大麻素产品的系统和方法,其中包括将第一相中的大麻素 前体与第二相中的大麻素合成酶接触,其中第一相和第二相基本不相溶或不相溶。本公开还提供了一种组合物,该组合物包含第一相中的大麻素前体和第二相中的大麻素合成酶,其中第一相和第二相基本不相溶或不相溶。
查看更多